Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) were first
introduced for the treatment of type 2 diabetes (T2D) in 2005. Despite the high efficacy and …

Cardiovascular events related to atherosclerosis are responsible for high morbidity and
mortality among patients with type 2 diabetes. Improvement in care, especially in early …

Peptide agonists of the glucagon-like peptide-1 receptor (GLP-1R) have revolutionized
diabetes therapy, but their use has been limited because they require injection. Herein, we …

Objective: Medical professionals are often challenged by lack of patient compliance with
pharmaceutical treatments. Research has shown that patients with diabetes have one of the …

Study Objectives: Few population-based studies have explored how excessive sleepiness
(ES) contributes to burden of illness among patients with obstructive sleep apnea (OSA) …

Aims To understand patient preferences for once‐daily oral versus once‐weekly injectable
type 2 diabetes mellitus (T2DM) medication administration profiles, and reasons for their …

Rates of obesity have risen over the past few decades. Subsequently, the popularity of the
pharmaceutical weight‐loss drug market has grown over the past few years to meet growing …

Background There is growing interest in Food is Medicine programs that incorporate food-
based interventions into health care for patients with diet-related conditions. Objectives We …

Objectives To achieve a better comprehension of the variability of perceptions, experiences
and needs in terms of sexual and vaginal health in postmenopausal women (PMW) from …

Utilizing peptides as therapeutic agents is considered an attractive approach for the
treatment of various diseases due to their high binding and selectivity to novel drug targets …